Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Tag: Epicutaneous Immunotherapy (EPIT)
DBV, Developers of Patch Therapies for Allergies to Peanuts, Milk and...
Dave Bloom
-
2021/01/08
The company announced they would be laying off 200 employees in Q1.
Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon?...
Dave Bloom
-
2020/06/30
Company is restructuring in anticipation of delays.
FDA Advisory Committee Meeting to Review Viaskin Peanut for the Treatment...
News Wire ~ 3rd Party Press Release
-
2020/02/22
Next step in the approval process for the therapy scheduled for May 15, 2020.
DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...
News Wire ~ 3rd Party Press Release
-
2020/01/09
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/10/04
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
News Wire ~ 3rd Party Press Release
-
2019/08/08
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not...
News Wire ~ 3rd Party Press Release
-
2019/07/11
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER...
News Wire ~ 3rd Party Press Release
-
2019/06/14
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Joint Statement on Peanut Allergy Therapy Review
News Wire ~ 3rd Party Press Release
-
2019/06/13
Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
Must See: 'ViewFinder: Food for Thought – Food Allergies'
Dave Bloom
-
2019/04/01
This documentary should be required viewing for everyone as the food allergy epidemic has affected so many in the community.
1
2
3
Page 1 of 3